Minimally Invasive Pancreaticoduodenectomy

The focused issue on “Minimally Invasive Pancreaticoduodenectomy”, guest edited by Dr. Barish Edil from the University of Colorado School of Medicine, aims to provide a comprehensive review of the ongoing understanding of the minimally invasive pancreaticoduodenectomy.

Read More>>

Science on Pancreatic Cancer

This focused issue on “Science on Pancreatic Cancer” is edited by Dr. Min Li, Department of Medicine, Surgery, and Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA, aims to provide a comprehensive review of the ongoing understanding of science on pancreatic cancer.

Read More>>

Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution

Patients who received adjuvant therapy after surgery had 2.1 times greater odds to be alive at 24 months after diagnosis than those who had surgery alone (P=0.015).

Read More>>

Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma

The addition of anti-PD1 antibody with GVAX and/or anti-CSF-1R antibody to gemcitabine improved the survival of mice with liver-metastatic pancreatic ductal adenocarcinoma (PDA).

Read More>>

Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities

The recognition of the essential role of epigenetic alterations in the development and progression of PDAC has revolutionized our knowledge of this disease and has immediate translational implications for targeting epigenetic abnormalities in PDAC for therapeutic purposes.

Read More>>

EUS- versus ERCP-guided biliary drainage for malignant biliary obstruction: evidence from randomized controlled studies

EUS-BD showed higher frequency of stent patency at 12 months. In addition, EUS-BD showed significant decreased incidence of procedure-associated pancreatitis [odds ratio (OR) =0.08, 95% confidence intervals (CI): 0.01 to 0.62, P=0.02) and reintervention rate (OR =0.25, 95% CI: 0.12 to 0.54, P=0.0004).

Read More>>

APC Annual Report 2019

Greetings from Editor-in-Chief and Editorial Office of Annals of Pancreatic Cancer!

We are glad to present the annual report of APC for the year of 2019. Please find attached the Annual Report below.

We would especially like to express our sincere gratitude to all supporters especially the editorial board members for all your support and contributions to Annals of Pancreatic Cancer from the inception of the journal. In 2020, we welcome more excellent international experts of the field to join and contribute to build APC a significant platform serving our scientists, doctors, patients and students in the field of pancreas.

Read More>>

Application of the CARE Guideline as reporting standard in Annals of Pancreatic Cancer

Annals of Pancreatic Cancer welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, Annals of Pancreatic Cancer will apply the CARE guidelines (1) as reporting standards for case reports starting from October 16, 2019. For any submission of case report after the date:

Read More>>

Why do we need a journal solely focused on the malignant diseases of the pancreas?

Pancreatic cancer has become the third leading cause of death from malignant diseases in both the United States and Europe. The incidence of pancreatic cancer is rising. Tremendous efforts have been devoted to basic and clinical research in pancreatic cancer. However, the outcome of pancreatic cancer has been minimally improved over the last thirty years. Such a profound sadness tells us that we should spend more efforts and be more focused on this disease. There had been no scientific journal that is solely focused on the malignant diseases of the pancreas. It is critical to have a media to rapidly disseminate research news and reports within the communities of pancreatic cancer researchers and have a venue to discuss the management strategies for pancreatic cancer among clinicians. This is why we are launching Annals of Pancreatic Cancer.

Read More>>